Michael Barbella, Managing Editor10.20.23
Microbot Medical Inc. has taken another step to advance the commercialization processes of the LIBERTY Robotic Surgical System by signing of a manufacturing agreement with B.Y. Medimor Ltd.
The agreement governs the LIBERTY Robotic Surgical System's manufacturing for its first-in-human clinical trial as well as for the initial LIBERTY systems that are expected to be marketed after completing regulatory requirements.
Medimor provides new product introduction (NPI) solutions and full turnkey manufacturing for medical devices as a one stop shop contract manufacturing service, including integration, parts cleaning, clean room assembly and testing.
“We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics," Microbot Chief Technology Officer/General Manager Simon Sharon said. “We believe the manufacturing agreement supports our efforts to deliver an advanced robotic system and facilitates our next steps."
The LIBERTY System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The company believes the LIBERTY System’s remote operation can potentially be the first to democratize endovascular interventional procedures.
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The agreement governs the LIBERTY Robotic Surgical System's manufacturing for its first-in-human clinical trial as well as for the initial LIBERTY systems that are expected to be marketed after completing regulatory requirements.
Medimor provides new product introduction (NPI) solutions and full turnkey manufacturing for medical devices as a one stop shop contract manufacturing service, including integration, parts cleaning, clean room assembly and testing.
“We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics," Microbot Chief Technology Officer/General Manager Simon Sharon said. “We believe the manufacturing agreement supports our efforts to deliver an advanced robotic system and facilitates our next steps."
The LIBERTY System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The company believes the LIBERTY System’s remote operation can potentially be the first to democratize endovascular interventional procedures.
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.